TransMedics Group Inc. reports first-quarter earnings after the close Tuesday, a closely watched release that will provide investors their first clean look at the organ-transplant technology company’s ...

TransMedics Group is leveraging its technological and logistical moat in organ transport, with OCS and NOP programs driving ...

TransMedics remains a Strong Buy after stellar growth, innovative technology, and founder-led leadership, with shares up 88% YTD, far outpacing the S&P 500. The company’s unique OCS platform, ...

TransMedics grew sales by 38% during the second quarter and saw its profit margins double compared to last year. Despite this, there may still be room for improvement, according to its CEO.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...

Innovations often (but not always) drive life-changing returns for the companies that engineer them and the people who get in on the ground floor. That's why investors should sometimes look toward ...

TransMedics Group unveiled its Controlled Hypothermic Organ Preservation System, or CHOPS, a new active cooling device for ...

Shares of next-generation transplant technology platform TransMedics (NASDAQ: TMDX) were up 21% as of noon ET on Friday, according to data provided by S&P Global Market Intelligence. TransMedics ...

TransMedics is helping improve organ transplantation thanks to its innovative organ storage system. The company has posted strong financial results over the past few years, and the stock is soaring.